From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
PD137889 structure.png
IUPAC name
3D model (JSmol)
Molar mass 201.313 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references

PD-137889 (N-methylhexahydrofluorenamine) is a chemical compound that is active as an NMDA receptor antagonist in the central nervous system at roughly 30 times the potency of the "flagship" of its class, ketamine,[1] and substitutes for phencyclidine in animal studies.[2][3][4] Ki [3H]TCP[a] binding = 27 nM versus ketamine's Ki = 860 nM.[5]

See also[edit]


  1. ^ Hays, Sheryl J.; Novak, Perry M.; Ortwine, Daniel F.; Bigge, Christopher F.; Colbry, Norman L.; Johnson, Graham; Lescosky, Leonard J.; Malone, Thomas C.; Michael, Andre (1993). "Synthesis and pharmacological evaluation of hexahydrofluorenamines as noncompetitive antagonists at the N-methyl-D-aspartate receptor". J Med Chem. 36 (6): 654–70. doi:10.1021/jm00058a002. PMID 8459395.
  2. ^ Nicholson, Katherine L.; Balster, Robert L. (2003). "Evaluation of the phencyclidine-like discriminative stimulus effects of novel NMDA channel blockers in rats". Psychopharmacology. 170 (2): 215–224. doi:10.1007/s00213-003-1527-6. PMID 2851738.
  3. ^ Bigge, Christopher F. (1993). "Structural requirements for the development of potent n-methyl-d-aspartic acid (NMDA) receptor antagonists". Biochemical Pharmacology. 45 (8): 1547–1561. doi:10.1016/0006-2952(93)90294-7.
  4. ^ Bigge, Christopher F.; Malone, Thomas C. (1993). "Overview: Agonists, Antagonists and Modulators of the N-methyl-D-aspartic acid (NMDA) and α-amino-3-hydroxy-5-methyl-4-isoxazolepropanoic acid (AMPA) Subtypes of Glutamate Receptors". Current Opinion on Therapeutic Patents. 3 (7): 951–989. doi:10.1517/13543776.3.7.951.
  5. ^ Polycyclic amine derivatives useful as cerebrovascular agents United States Patent; Coughenour, et al. Family ID: 22686445 Appl. #07/186,834
  1. ^ [3H]N-[1-(2-thienyl)cyclohex-yl]piperidine